TSHA Taysha Gene Therapies, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1806310 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.1%
TTM net income YoY-56.1%
TTM EPS YoY-27.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-2,935.4%
Net margin-2,844.6%
FCF margin-2,582.6%
EBITDA margin-2,913.6%
Returns
ROE-54.2%
ROA-41.5%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.13x
Current ratio18.56x
Interest coverage-5,193.77x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | — |
| R&D expense | $86.40M | $66.00M | $56.78M | $91.17M | $131.94M |
| SG&A expense | $33.87M | $28.95M | $30.05M | $37.36M | $41.32M |
| Operating income | -$110.50M | -$91.46M | -$72.44M | -$162.45M | -$173.27M |
| Interest expense | $63,000 | $102,000 | $5.00M | $3.80M | $1.43M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M |
| EBITDA | -$109.35M | -$90.21M | -$71.07M | -$161.28M | -$172.78M |
| EPS (basic) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 |
| EPS (diluted) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 |
| Weighted avg. shares (diluted) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M |
| Balance sheet | |||||
| Cash & equivalents | $319.77M | $139.04M | $143.94M | $87.88M | $149.10M |
| Current assets | $324.65M | $142.13M | $149.87M | $96.42M | $159.60M |
| PP&E, net | $6.74M | $7.49M | $10.83M | $14.96M | $50.61M |
| Total assets | $343.32M | $160.36M | $172.73M | $126.28M | $213.96M |
| Current liabilities | $26.55M | $26.23M | $36.76M | $62.79M | $51.75M |
| Long-term debt | $50.11M | $43.94M | $40.51M | $37.97M | $37.19M |
| Total debt | $50.11M | $43.94M | $40.51M | $37.97M | $37.19M |
| Total liabilities | $96.38M | $88.84M | $97.79M | $125.33M | $118.57M |
| Shareholders' equity | $246.94M | $71.53M | $74.94M | $949,000 | $95.38M |
| Net debt | -$269.66M | -$95.09M | -$103.43M | -$49.91M | -$111.91M |
| Shares outstanding | 285.05M | 204.94M | 186.96M | 63.21M | 38.47M |
| Cash flow statement | |||||
| Operating cash flow | -$93.09M | -$81.22M | -$73.02M | -$88.39M | -$117.04M |
| Capital expenditure | $738,000 | $374,000 | $3.87M | $20.62M | $15.30M |
| Free cash flow | -$93.83M | -$81.60M | -$76.89M | -$109.01M | -$132.35M |
| Investing cash flow | -$604,000 | -$363,000 | -$7.35M | -$24.93M | -$21.55M |
| Financing cash flow | $274.59M | $76.68M | $136.39M | $52.10M | $39.08M |
| Depreciation & amortization | $1.15M | $1.25M | $1.37M | $1.17M | $492,000 |
| Stock-based compensation | $13.30M | $13.10M | $7.91M | $18.04M | $18.18M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.